Medical DirectorIndiana Hemophilia & Thrombosis Center, Indianapolis, IN, USAIndianapolis, Indiana, United States
PB0186 - Results from BeneGene-1 Study: Prospective collection of bleeding rate in hemophilia B patients prior to phase 3 study (BeneGene-2) of fidanacogene elaparvovec
Sunday, June 25, 202318:30 – 19:30 ET
OC 52.3 - Efficacy and Safety of Fidanacogene Elaparvovec in Adults with Moderately Severe or Severe Hemophilia B: Results from the Phase 3 BENEGENE-2 Gene Therapy Trial
Tuesday, June 27, 202311:15 – 11:30 ET
OC 59.3 - Pooled Safety Results from the Multidose explorer Studies of Concizumab in Patients with Haemophilia
Tuesday, June 27, 202315:15 – 15:30 ET
OC 75.1 - First US Rare Bleeding Disorder Genotype-Phenotype Registry (ATHN 10) Discovers Many Individuals with Both Novel and Multiple Variants Using a Customized 30-Gene Next-Generation Sequencing Panel
Wednesday, June 28, 202310:15 – 10:30 ET
